TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26499250
Drug: tDCS‐control cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS‐control cognitive training (DCS‐CC)
Study: 23255145
Drug: Topical perfluorodecalin
Normalized name: Perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical perfluorodecalin (PFD) with R0 method (3 passes)
Study: 21254315
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (4 weeks)
Study: 19497597
Drug: ExCHO -
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ExCHO - 80-minute resistance exercise bout while consuming CHO (approximately 77 g CHO, 306 kcal)
Study: 11695214
Drug: Colgate Winterfresh
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Winterfresh Gel Fluoride Toothpaste
Study: 9585725
Drug: Tomoxetine (76
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomoxetine (76 mg/day)
Study: 791107
Drug: Doxycycline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (2 mg/kg at the beginning, at 12 h, and once daily)
Study: 791107
Drug: Tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride (administered at 6-h intervals)
Study: 28349044
Drug: VPZ-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPZ-based treatment (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)
Study: 28349044
Drug: PPI-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based treatment (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)
Study: 28349044
Drug: VPZ-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPZ-based treatment
Study: 28349044
Drug: PPI-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based treatment
Study: 18053998
Drug: Synthetic conjugated
Normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic conjugated estrogens B (0.3 mg/d)
Study: 17212913
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (medications, physical therapy, epidural steroid injections)
Study: 11349266
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF), 1 g twice daily intravenously followed by 1.5 g twice daily orally
Study: 11349266
Drug: Azathioprine (AZA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (AZA), 1.0 to 2.0 mg/kg/d intravenously followed by oral administration
Study: 3435159
Drug: Human normal
Normalized name: Human normal immunoglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human normal immunoglobulin (50 mg/kg) administered weekly via intramuscular injection
Study: 25558162
Drug: Varunadi Ghritha,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varunadi Ghritha, 5gms twice daily for one year
Study: 18538051
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg kg(‐1) loading dose followed by 0.2 microg kg(‐1) h(‐1))
Study: 18538051
Drug: Midazolam/Fentanyl (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam/Fentanyl (0.05 mg kg(‐1) midazolam and 1 microg kg(‐1) fentanyl)
Study: 27507005
Drug: Glucose drink
Normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose drink (0.75 g/kg body weight)
Study: 27507005
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein drink (0.75 g/kg body weight)
Study: 18341431
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost (LA) administered once-daily for 3 months after switching from beta-blockers
Study: 18341431
Drug: Topical beta-blockers
Normalized name: Beta-HC Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beta-blockers (carteolol hydrochloride, nipradilol, betaxolol hydrochloride) administered twice-daily for 3 months before switching to LA
Study: 12432966
Drug: Extended-release Adderall
Normalized name: amphetamine / dextroamphetamine Extended Release Oral Capsule [Adderall]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release Adderall 20 mg (formulation A)
Study: 12432966
Drug: Extended-release Adderall
Normalized name: amphetamine / dextroamphetamine Extended Release Oral Capsule [Adderall]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release Adderall 20 mg (formulation B)
Study: 12432966
Drug: Extended-release Adderall
Normalized name: amphetamine / dextroamphetamine Extended Release Oral Capsule [Adderall]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release Adderall 20 mg (formulation C)
Study: 12432966
Drug: SLI381 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 30 mg (intact capsule)
Study: 12432966
Drug: SLI381 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 30 mg (sprinkled in applesauce)
Study: 8582462
Drug: Dextropropoxyphene napsylate
Normalized name: Dextropropoxyphene napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene napsylate 100 mg
Study: 8582462
Drug: Dextropropoxyphene napsylate
Normalized name: Dextropropoxyphene napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene napsylate 200 mg
Study: 3407612
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Zn/d supplementation for 28 days
Study: 11601116
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy (pool exercise therapy)
Study: 9013436
Drug: High heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High heart rate intensity exercise (HI, N = 8) - exercised at a mean heart rate of 163 bpm for 40 to 45 minutes approximately four times weekly.
Study: 9013436
Drug: Low heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low heart rate intensity exercise (LI, N = 7) - exercised at a mean heart rate of 132 bpm for 40 to 45 minutes approximately four times weekly.
Study: 3928919
Drug: BCAA (valine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (valine, leucine, isoleucine) at 0.5 g/kg/day
Study: 3928919
Drug: BCAA (valine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (valine, leucine, isoleucine) at 1.0 g/kg/day
Study: 3928919
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg of essential and nonessential AA solution with a prevalence of BCAA
Study: 23083787
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily (titrated to 50 mg)
Study: 19903864
Drug: Pravastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin treatment (4 weeks)
Study: 18817955
Drug: Naftopidil 75
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 75 mg after dinner for 6 weeks
Study: 11429021
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1 g tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)
Study: 11429021
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (400 mg tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)
Study: 8262130
Drug: Leuprolide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide plus flutamide (250 mg p.o. t.i.d.)
Study: 4023977
Drug: Inhaled lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lignocaine
Study: 24906665
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis for children with dilating VUR
Study: 19883384
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) - Lindynette® and Cilest®
Study: 19281738
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous calcitriol
Study: 19281738
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral calcitriol
Study: 17002607
Drug: HE2000 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HE2000 (50 mg)
Study: 17002607
Drug: HE2000 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HE2000 (50 mg or 100 mg)
Study: 20718734
Drug: Haem arginate
Normalized name: Haem arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haem arginate (HA) infusion
Study: 16446690
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CS) supplementation (3,600 mg x day‐1 for 14 days)
Study: 1328358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormonal therapy)
Study: 2754149
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate aerosol (MPA) inhalation and placebo injection
Study: 2754149
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection (EPI) and inhaled placebo
Study: 2754149
Drug: Crossover comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover comparison regimen after initial treatment
Study: 1278718
Drug: Control (secretin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (secretin and cholecystokinin without drugs)
Study: 2841841
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g soy polysaccharide
Study: 2841841
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g soy polysaccharide
Study: 17986035
Drug: 0.2% solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% solutions
Study: 17986035
Drug: 0.25% solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% solutions
Study: 15659490
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) with cyclophosphamide, mitoxantrone, and etoposide followed by peripheral-blood stem-cell transplantation, repeated after 6 weeks.
Study: 15659490
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination therapy with doxorubicin and paclitaxel (AT).
Study: 10194129
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell receptor (TCR) variable (V) region expression assessment using monoclonal antibodies specific for different V region families (alpha or beta) in combination with anti‐CD4 or anti‐CD8.
Study: 7749881
Drug: Atorvastatin 2.5
Normalized name: amlodipine-atorvastatin 2.5 mg-10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 2.5 mg
Study: 380736
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metronidazole as an intravenous infusion during the operation
Study: 29101708
Drug: PBMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT with dose of 15 J per site
Study: 29101708
Drug: PBMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT with doses of 30 J per site
Study: 29101708
Drug: PBMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT with doses of 60 J per site
Study: 24446755
Drug: 20 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 sessions of NB‐UVB treatment before transplantation
Study: 24446755
Drug: 30 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 sessions of NB‐UVB treatment after transplantation
Study: 24446755
Drug: 20 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 sessions of NB‐UVB treatment before transplantation and 30 sessions after transplantation
Study: 24446755
Drug: Only transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only transplantation (no NB‐UVB treatment)
Study: 22055478
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition supplemented with L-glutamine (30 g) for 2 days
Study: 22055478
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition with calcium caseinate (30 g) for 2 days
Study: 22055478
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition supplemented with L-glutamine (30 g) followed by calcium caseinate (30 g)
Study: 22055478
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition with calcium caseinate (30 g) followed by L-glutamine (30 g)
Study: 19345944
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of oral mifepristone followed 48 hours later with 400 microg of oral misoprostol, administered either at home or at the clinic
Study: 19345944
Drug: Home administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home administration of misoprostol
Study: 15482522
Drug: Homogenised kiwifruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homogenised kiwifruit preparation
Study: 11864944
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g administered every 12 hours
Study: 8657964
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole (1 g i.v.)
Study: 8657964
Drug: Rectal metronidazole
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal metronidazole (1 g suppository)
Study: 8657964
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (gentamycin 80 mg i.v. + metronidazole 1 g i.v. or suppository)
Study: 2158192
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus extract, administered intraperitoneally (i.p.)
Study: 6451235
Drug: Nicotinamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (500 mg twice daily)
Study: 30819520
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (120 mg)
Study: 30819520
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone (1 mg)
Study: 30819520
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (120 mg) in patients with nephrolithiasis
Study: 30819520
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone (1 mg) in patients with nephrolithiasis
Study: 28724183
Drug: Myo-Inositol-based supplement
Normalized name: myo-inositol trispyrophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-Inositol-based supplement (Folandrol®, Exeltis, Hungary) for two months and semen incubation with 2 mg/ml of Myo-Inositol for 2 hours before PICSI procedures.
Study: 28724183
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during the same time range).
Study: 19943918
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive nutritional care (BSNC) plus parenteral nutrition (PN)
Study: 17299067
Drug: l-T(4) (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-T(4) (1.3 microg/kg daily) for 24 months
Study: 7752912
Drug: 75-g fructose
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-g fructose solution with 300 mg caffeine
Study: 7752912
Drug: 75-g glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-g glucose solution with 300 mg caffeine
Study: 7752912
Drug: 75-g fructose
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-g fructose solution without caffeine (placebo)
Study: 7752912
Drug: 75-g glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-g glucose solution without caffeine (placebo)
Study: 2306439
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous indomethacin one hour beforehand
Study: 2306439
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (comparison group)
Study: 7002355
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg twice daily)
Study: 7002355
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Sulfinpyrazone
Study: 22314425
Drug: GS-5885 1
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5885 1 mg QD
Study: 22314425
Drug: GS-5885 3
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5885 3 mg QD
Study: 22314425
Drug: GS-5885 10
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5885 10 mg QD
Study: 22314425
Drug: GS-5885 30
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5885 30 mg QD
Study: 22314425
Drug: GS-5885 90
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5885 90 mg QD
Study: 10782903
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 14-16 mg/kg/day
Study: 8903001
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (30 mg; i.m.)
Study: 8903001
Drug: Dipyrone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1.0 g; 2.5 g; i.v.)
Study: 1853794
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic treatment
Study: 1853794
Drug: Conventional-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose antibiotic treatment
Study: 6191994
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg)
Study: 30590537
Drug: Ivermectin 300
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 300 mcg/kg/day
Study: 30590537
Drug: Ivermectin 600
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 600 mcg/kg/day
Study: 29793404
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment for GDM
Study: 22433473
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (520 mg/day of elemental magnesium)
Study: 22433473
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (295.8 mg/day of elemental magnesium)
Study: 16208149
Drug: Telmisartan (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (20, 40, or 80 mg)
Study: 10411366
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination therapy (5 mg enalapril + 5 mg felodipine ER once daily)
Study: 10411366
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of monotherapy (10 mg enalapril once daily)
Study: 1443507
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg ketamine racemate
Study: 1443507
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg S-(+)-Ketamine
Study: 1443507
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg S-(+)-Ketamine after 0.1 mg/kg midazolam premedication
Study: 29804059
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (60 mg/kg/day of DHA)
Study: 24499206
Drug: Audio feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio feedback during stair-climbing therapy
Study: 20838049
Drug: Permanent GES
Normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent GES implant after TPGES.
Study: 18973936
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (1 mg twice daily)
Study: 18973936
Drug: Montelukast (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4 mg daily)
Study: 12624285
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g over 30 minutes)
Study: 3277578
Drug: Comparison treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison treatment (hospitalization without family intervention)
Study: 31992358
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (lifestyle advice, pharmacotherapy with bulking agents or antidiarrheal medication)
Study: 20361901
Drug: Divalproex extended
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex extended release (ER) at 15 mg/kg/d titrated to a maximum of 30 mg/kg/d
Study: 18403559
Drug: Intravenous rtPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rtPA